Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells - PubMed (original) (raw)
. 2006 Sep 1;215(2):208-17.
doi: 10.1016/j.taap.2006.02.005. Epub 2006 Mar 31.
Affiliations
- PMID: 16580038
- DOI: 10.1016/j.taap.2006.02.005
Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells
Sara Rodríguez-Enríquez et al. Toxicol Appl Pharmacol. 2006.
Abstract
The relationship between cell proliferation and the rates of glycolysis and oxidative phosphorylation in HeLa (human) and AS-30D (rodent) tumor cells was evaluated. In glutamine plus glucose medium, both tumor lines grew optimally. Mitochondria were the predominant source of ATP in both cell types (66-75%), despite an active glycolysis. In glucose-free medium with glutamine, proliferation of both lines diminished by 30% but oxidative phosphorylation and the cytosolic ATP level increased by 50%. In glutamine-free medium with glucose, proliferation, oxidative phosphorylation and ATP concentration diminished drastically, although the cells were viable. Oligomycin, in medium with glutamine plus glucose, abolished growth of both tumor lines, indicating an essential role of mitochondrial ATP for tumor progression. The presumed mitochondrial inhibitors rhodamines 123 and 6G, and casiopeina II-gly, inhibited tumor cell proliferation and oxidative phosphorylation, but also glycolysis. In contrast, gossypol, iodoacetate and arsenite strongly blocked glycolysis; however, they did not affect tumor proliferation or mitochondrial metabolism. Growth of both tumor lines was highly sensitive to rhodamines and casiopeina II-gly, with IC(50) values for HeLa cells lower than 0.5 microM, whereas viability and proliferation of human lymphocytes were not affected by these drugs (IC(50) > 30 microM). Moreover, rhodamine 6G and casiopeina II-gly, at micromolar doses, prolonged the survival of animals bearing i.p. implanted AS-30D hepatoma. It is concluded that fast-growing tumor cells have a predominantly oxidative type of metabolism, which might be a potential therapeutic target.
Similar articles
- Contributions of glycolysis and oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D hepatoma cells.
Nakashima RA, Paggi MG, Pedersen PL. Nakashima RA, et al. Cancer Res. 1984 Dec;44(12 Pt 1):5702-6. Cancer Res. 1984. PMID: 6498833 - Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation.
Marín-Hernández A, Gallardo-Pérez JC, López-Ramírez SY, García-García JD, Rodríguez-Zavala JS, Ruiz-Ramírez L, Gracia-Mora I, Zentella-Dehesa A, Sosa-Garrocho M, Macías-Silva M, Moreno-Sánchez R, Rodríguez-Enríquez S. Marín-Hernández A, et al. Arch Toxicol. 2012 May;86(5):753-66. doi: 10.1007/s00204-012-0809-3. Epub 2012 Feb 18. Arch Toxicol. 2012. PMID: 22349057 - Substrate oxidation and ATP supply in AS-30D hepatoma cells.
Rodríguez-Enríquez S, Torres-Márquez ME, Moreno-Sánchez R. Rodríguez-Enríquez S, et al. Arch Biochem Biophys. 2000 Mar 1;375(1):21-30. doi: 10.1006/abbi.1999.1582. Arch Biochem Biophys. 2000. PMID: 10683245 - Energy metabolism in tumor cells.
Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Moreno-Sánchez R, et al. FEBS J. 2007 Mar;274(6):1393-418. doi: 10.1111/j.1742-4658.2007.05686.x. FEBS J. 2007. PMID: 17302740 Review. - The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells?
Moreno-Sánchez R, Rodríguez-Enríquez S, Saavedra E, Marín-Hernández A, Gallardo-Pérez JC. Moreno-Sánchez R, et al. Biofactors. 2009 Mar-Apr;35(2):209-25. doi: 10.1002/biof.31. Biofactors. 2009. PMID: 19449450 Review.
Cited by
- Unraveling the Mystery of Energy-Sensing Enzymes and Signaling Pathways in Tumorigenesis and Their Potential as Therapeutic Targets for Cancer.
Mirza Z, Karim S. Mirza Z, et al. Cells. 2024 Sep 2;13(17):1474. doi: 10.3390/cells13171474. Cells. 2024. PMID: 39273044 Free PMC article. Review. - The multifaceted role of quercetin derived from its mitochondrial mechanism.
Carrillo-Garmendia A, Madrigal-Perez LA, Regalado-Gonzalez C. Carrillo-Garmendia A, et al. Mol Cell Biochem. 2024 Aug;479(8):1985-1997. doi: 10.1007/s11010-023-04833-w. Epub 2023 Sep 1. Mol Cell Biochem. 2024. PMID: 37656383 Review. - 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model.
Slater K, Bosch R, Smith KF, Jahangir CA, Garcia-Mulero S, Rahman A, O'Connell F, Piulats JM, O'Neill V, Horgan N, Coupland SE, O'Sullivan J, Gallagher WM, Villanueva A, Kennedy BN. Slater K, et al. Front Med (Lausanne). 2023 Jan 9;9:1036322. doi: 10.3389/fmed.2022.1036322. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36698840 Free PMC article. - Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors.
Annese T, Errede M, d'Amati A, De Giorgis M, Lorusso L, Tamma R, Ribatti D. Annese T, et al. Diagnostics (Basel). 2022 Dec 10;12(12):3120. doi: 10.3390/diagnostics12123120. Diagnostics (Basel). 2022. PMID: 36553127 Free PMC article. - Double Immunohistochemical Staining on Formalin-Fixed Paraffin-Embedded Tissue Samples to Study Vascular Co-option.
Annese T, Errede M, De Giorgis M, Lorusso L, Tamma R, Ribatti D. Annese T, et al. Methods Mol Biol. 2023;2572:101-116. doi: 10.1007/978-1-0716-2703-7_8. Methods Mol Biol. 2023. PMID: 36161411
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials